Product Description
AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01129193)
Mechanisms of Action: HDAC6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alison Walker
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Renal Cell Carcinoma|Acute Myeloid Leukemia|Kidney Diseases|Meningioma|Neurilemmoma|Neurofibromatosis 2|Neuroma, Acoustic|Neurofibromatoses|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Lymphoproliferative Disorders|Adult T-Cell Leukemia-Lymphoma|Plasmablastic Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|Immunoblastic Lymphadenopathy|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Multiple Myeloma|Waldenstrom Macroglobulinemia|Leukemia, Plasma Cell|Sarcoma|Prolymphocytic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Lymphomatoid Granulomatosis|T-Cell Peripheral Lymphoma|Large-Cell Immunoblastic Lymphoma|Testicular Cancer|Burkitt Lymphoma|Mycosis Fungoides|Intraocular Lymphoma|Large-Cell Anaplastic Lymphoma|Follicular Lymphoma|T-Cell Cutaneous Lymphoma|Prolymphocytic T-Cell Leukemia|Sezary Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02569320 |
OSU-15004 | P1 |
Completed |
Multiple Myeloma |
2020-11-14 |
2021-06-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT02282917 |
14-078H | P1 |
Terminated |
Neurofibromatoses|Neuroma, Acoustic|Neurofibromatosis 2|Neurilemmoma|Meningioma |
2017-05-30 |
2022-05-12 |
Primary Endpoints |
|
NCT01129193 |
OSU-09102 | P1 |
Completed |
T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma|Prolymphocytic T-Cell Leukemia|Sezary Syndrome|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma|Extranodal NK-T-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Follicular Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphomatoid Granulomatosis|Lymphocytic Chronic B-Cell Leukemia|Immunoblastic Lymphadenopathy|Lymphoproliferative Disorders|Intraocular Lymphoma|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Plasmablastic Lymphoma|Adult T-Cell Leukemia-Lymphoma|Prolymphocytic B-Cell Leukemia|Mycosis Fungoides|Testicular Cancer|Burkitt Lymphoma|Leukemia, Plasma Cell|Large-Cell Anaplastic Lymphoma|Prolymphocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Waldenstrom Macroglobulinemia|Chronic Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma |
2017-01-07 |
2019-03-19 |
Treatments |
|
NCT02795819 |
MCC-14-10774 | P1 |
Terminated |
Renal Cell Carcinoma|Sarcoma|Kidney Diseases |
2016-11-24 |
2019-04-04 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT01798901 |
OSU-11130 | P1 |
Completed |
Acute Myeloid Leukemia |
2015-02-19 |
2019-03-19 |
Treatments |
